Dear All,
As expected, I have just heard that NICE have decided to defer the FAD on dasatinib/nilotinib for imatinib intolerance until they have determined their guidance for the IM resistant population, which is in turn a part of the review of TA70 (including high dose IM -as well as dasatinib and nilotinib) with an expected date for that preliminary recommendation (ACD) in April 2011. They take the view that intolerance guidance could be influenced by the appraisal outcome of IM resistant population. Until that time decisions on treatment stand as they are today.... within local health authority policy.
NICE will publish more information on the website 'shortly'
Of course this is good news for most, although does not help those struggling with local authorities who are refusing to transfer therapy, in which case the 'exceptional treatment panels' still rule.
Sandy